Axsome Therapeutics (AXSM) Earnings Date & Reports

Key Takeaways

• Revenue: Axsome Therapeutics reported Q2 2026 total revenue of $218.38 million, a 46% increase from $150.04 million in the same quarter last year, though slightly below the consensus estimate of approximately $221–225 million.
• Earnings: The company posted a net loss of $51.3 million, or $0.99 per share, which was in line with the Zacks Consensus Estimate of -$0.99.
• Auvelity Performance: Auvelity generated $180.3 million in net product sales, up 51% year-over-year, driven by expanded market access and the June launch for Alzheimer's disease agitation.
• Pipeline Progress: The FDA accepted Axsome's new drug application for AXS-12 in narcolepsy, assigning a target action date (PDUFA) of May 1, 2027.
• Cash Runway: Axsome ended the quarter with approximately $320 million in cash and cash equivalents, which management expects will fund operations into cash-flow positivity.

Earnings Context and Why It Matters

Axsome Therapeutics' Q2 2026 report arrives at a pivotal moment for the neuroscience-focused biopharmaceutical company. With three commercialized products now on the market — Auvelity, Sunosi, and Symbravo — and a pipeline spanning major depressive disorder, Alzheimer's disease agitation, narcolepsy, and smoking cessation, investors are closely tracking whether commercial traction can outpace spending. The quarter also marked the launch of Auvelity for Alzheimer's disease agitation, a significant label expansion that analysts view as a potential growth catalyst. Revenue growth of 46% signals strong demand, but the slight top-line miss and ongoing net losses underscore the balancing act between aggressive commercialization and achieving profitability.

Reported Results

Axsome Therapeutics reported total net product revenue of $218.38 million for the second quarter ended June 30, 2026, falling short of the Zacks Consensus Estimate of $224.52 million by approximately 2.74%. Net loss came in at $51.3 million, or $0.99 per share, matching the Zacks Consensus Estimate but widening from a net loss of $48 million, or $0.97 per share, in the prior-year period.

Breaking down product performance, Auvelity — the company's lead asset for major depressive disorder and now Alzheimer's disease agitation — delivered $180.3 million in net product sales, a 51% year-over-year increase and an 18% sequential gain from Q1 2026. Total Auvelity prescriptions reached roughly 266,000, up 34% from a year ago.

Sunosi, indicated for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea, contributed $35.8 million in total revenue, including $33.8 million in net product sales and $2.0 million in royalty and milestone revenue. That represented approximately 19% growth from the prior-year quarter.

Symbravo, the company's acute migraine treatment, recorded $2.3 million in net product sales, down from $4.1 million in Q1 2026. Management attributed the sequential decline primarily to a prior-period adjustment and increased utilization of a patient-service program, noting that the unusually high gross-to-net discount in the high-80% range is expected to normalize through the remainder of the year.

Cost of revenue was $13.6 million, or approximately 6% of total net revenue. Selling, general, and administrative (SG&A) expenses rose sharply to $208.1 million from $130.3 million a year earlier, reflecting the expanded Auvelity sales force of approximately 630 representatives and commercialization activities for the Alzheimer's agitation launch. Research and development (R&D) expenses declined modestly to $46.2 million from $49.5 million, driven by lower costs tied to AXS-05 and AXS-14 programs.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on a wide range of criteria including technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For those tracking biopharmaceutical companies like Axsome Therapeutics, the screener can help identify trade ideas, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. Whether you are looking for earnings-season setups or longer-term sector plays, the AI Screener offers a streamlined way to surface actionable ideas.

Market Reaction and Investor Sentiment

Following the August 10 earnings release, Axsome shares showed modestly positive movement in pre-market trading, according to Investing.com data, suggesting investors were prepared for the slight revenue miss and focused instead on encouraging early signals from the Alzheimer's agitation launch. Heading into the report, analyst sentiment was broadly positive, with a consensus "Moderate Buy" rating and an average price target of approximately $265.55 — roughly 25% above pre-earnings levels. The stock had gained about 16.5% year-to-date, outperforming the S&P 500. However, concerns persist around rising SG&A expenses, Symbravo's uneven ramp, and whether Auvelity's label expansion can accelerate revenue growth enough to offset spending. Insider selling of approximately $46.7 million during the quarter also drew attention, though the transactions were largely tied to tax-withholding obligations related to equity vesting.

Forward Outlook and Key Factors to Monitor

Axsome enters the second half of 2026 with several important catalysts on the horizon. The most immediate focus for investors will be early prescription data for Auvelity in Alzheimer's disease agitation. During the first eight weeks after launch, new-to-brand prescriptions among patients aged 65 and older rose 126% compared with the same period in the prior quarter, an encouraging early signal. As the expanded sales force of approximately 630 representatives gains traction, prescription trends in both community and long-term care settings will be closely scrutinized.

On the regulatory front, the FDA's acceptance of the AXS-12 new drug application for cataplexy in narcolepsy sets up a PDUFA (Prescription Drug User Fee Act) target action date of May 1, 2027. This represents a significant potential approval milestone that could add another commercial asset to Axsome's portfolio.

Clinical catalysts also loom large. The company expects to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation during the third quarter of 2026. Additionally, topline results from the Phase 3 ENGAGE trial of solriamfetol in binge eating disorder are anticipated in the fourth quarter of 2026, with the Phase 3 SUSTAIN trial in shift work disorder expected to read out in 2027.

On the financial side, investors should monitor whether SG&A spending moderates following the sales force expansion, whether Symbravo's gross-to-net discount normalizes as management expects, and whether Auvelity's growth trajectory can sustain momentum across both major depressive disorder and the new Alzheimer's agitation indication. The company's cash position of roughly $320 million provides a buffer, but the path to cash-flow positivity will depend on continued double-digit revenue growth and disciplined expense management.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations